| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
25024 |
| Drug |
Semaglutide |
| Brand |
Wegovy® |
| Indication |
Semaglutide (Wegovy®) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (BMI) of • ≥30kg/m2 (obesity), or • ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. |
| Rapid review commissioned |
21/03/2025 |
| Rapid review completed |
14/05/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of semaglutide (Wegovy®) for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
29/05/2025 |
| Pre-submission consultation with Applicant |
03/09/2025 |
